Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Semax/Selank
Pre-mixed blend of Semax (an ACTH(4-10) analog) and Selank (a heptapeptide tuftsin analog), both developed at the Russian Institute of Molecular Genetics. The individual compounds are registered as prescription drugs in Russia (intranasal); neither is FDA- or EMA-approved. The blend itself is NOT clinically validated — no controlled trial has tested Semax and Selank co-administered.
Extrapolated from component-level research (primarily Russian-language): Semax has been reported to upregulate BDNF/NGF expression and modulate monoaminergic tone; Selank has been reported to modulate GABA-A signaling, enkephalin-degrading enzymes, and serotonergic tone. Any additive effect of co-administration has not been studied in controlled trials.
Each component has separate published research, largely in Russian literature, with limited independent Western replication. The blend format is a vendor convention, not a clinically validated protocol.
Typical Dose
5mg/5mg per vial
Frequency
Daily
Route
Intranasal, SubQ
Notes
Standard size: 10mg (5/5). Available as nasal spray or lyophilized powder for SubQ. Store at 2-8°C.
Aggregated from 12 lab-verified Certificates of Analysis uploaded directly by labs. Purity averages exclude values outside [50%, 100%] to filter unit-misreads.
COAs
12
Verified labs
0
Avg purity
99.41%
±0.41%
Endotoxin tested
42%
This platform provides informational tools only, not medical advice. This information is for educational purposes only. Consult a licensed provider.
Disclosed Labs